» Articles » PMID: 36600404

Comparing RNA-sequencing Datasets from Astrocytes, Oligodendrocytes, and Microglia in Multiple Sclerosis Identifies Novel Dysregulated Genes Relevant to Inflammation and Myelination

Overview
Journal WIREs Mech Dis
Date 2023 Jan 4
PMID 36600404
Authors
Affiliations
Soon will be listed here.
Abstract

Central nervous system (CNS) inflammation is a key factor in multiple sclerosis (MS). Invasion of peripheral immune cells into the CNS resulting from an unknown signal or combination of signals results in activation of resident immune cells and the hallmark feature of the disease: demyelinating lesions. These lesion sites are an amalgam of reactive peripheral and central immune cells, astrocytes, damaged and dying oligodendrocytes, and injured neurons and axons. Sustained inflammation affects cells directly located within the lesion site and further abnormalities are apparent diffusely throughout normal-appearing white matter and grey matter. It is only relatively recently, using animal models, new tissue sampling techniques, and next-generation sequencing, that molecular changes occurring in CNS resident cells have been broadly captured. Advances in cell isolation through Fluorescence Activated Cell Sorting (FACS) and laser-capture microdissection together with the emergence of single-cell sequencing have enabled researchers to investigate changes in gene expression in astrocytes, microglia, and oligodendrocytes derived from animal models of MS as well as from primary patient tissue. The contribution of some dysregulated pathways has been followed up in individual studies; however, corroborating results often go unreported between sequencing studies. To this end, we have consolidated results from numerous RNA-sequencing studies to identify and review novel patterns of differentially regulated genes and pathways occurring within CNS glial cells in MS. This article is categorized under: Neurological Diseases > Molecular and Cellular Physiology.

Citing Articles

Conditioned medium derived from mesenchymal stem cells and spinal cord injury: A review of the current therapeutic capacities.

Kaka G, Modarresi F IBRO Neurosci Rep. 2025; 18:293-299.

PMID: 40026846 PMC: 11869877. DOI: 10.1016/j.ibneur.2025.02.004.


Dorsoventral photobiomodulation therapy safely reduces inflammation and sensorimotor deficits in a mouse model of multiple sclerosis.

Escarrat V, Reato D, Blivet G, Touchon J, Rougon G, Bos R J Neuroinflammation. 2024; 21(1):321.

PMID: 39696356 PMC: 11656913. DOI: 10.1186/s12974-024-03294-2.


Senolytic treatment diminishes microglia and decreases severity of experimental autoimmune encephalomyelitis.

Drake S, Zaman A, Gianfelice C, Hua E, Heale K, Afanasiev E J Neuroinflammation. 2024; 21(1):283.

PMID: 39487537 PMC: 11529445. DOI: 10.1186/s12974-024-03278-2.


Mesenchymal Stem Cells-based Cell-free Therapy Targeting Neuroinflammation.

Xu H, Wang B, Li A, Wen J, Su H, Qin D Aging Dis. 2024; 15(3):965-976.

PMID: 38722791 PMC: 11081161. DOI: 10.14336/AD.2023.0904.